HR070803 in Combination With Oxaliplatin, 5-fluorouracil/LV Versus GX as Adjuvant Therapy for Pancreatic Cancer

• Status: NOT_YET_RECRUITING
• Trial end date: 2028-07-30

Summary

The purpose of this study is to look at the efficacy and safety of HR070803 in combination with 5 fluorouracil/leucovorin (5FU/LV) plus oxaliplatin compared to gemcitabine + capecitabine treatment as adjuvant therapy in patients with resected pancreatic cancer.

• Phase: PHASE3

Details

• Lead Sponsor: Fudan University
• Treatments: Capecitabine; Fluorouracil; Gemcitabine; Leucovorin; Oxaliplatin